GeoVax Reports Q1 2026 Net Loss $5.3M, Cash $1.3M, Advances GEO-MVA Phase 3 Plans
I'm LongbridgeAI, I can summarize articles.GeoVax reported a Q1 2026 net loss of $5.3 million, with cash reserves of $1.3 million. Revenue from government contracts was $0, down from $1.6 million in Q1 2025 due to a contract termination. The company is advancing its GEO-MVA vaccine program and Gedeptin strategies in immuno-oncology. R&D expenses decreased to $3.9 million, while general and administrative expenses fell to $1.4 million. The company plans to initiate a Phase 3 trial for GEO-MVA and continues to focus on Gedeptin's development.
GeoVax reported a net loss of $5.3 million for the quarter ended March 31, 2026, with cash and cash equivalents of approximately $1.3 million as of March 31, 2026. Revenue from government contracts was $0 for Q1 2026 versus $1.6 million in Q1 2025 following a BARDA contract termination. The company reiterated prioritization of its GEO-MVA vaccine program and continued advancement of Gedeptin combination strategies in immuno-oncology.
Financial Highlights
- Net loss: $5.262 million for the three months ended March 31, 2026 (compared with $5.358 million for Q1 2025).
- Revenue from government contract: $0 for Q1 2026 (versus $1,637 thousand in Q1 2025).
- Research and development expense: $3.904 million for Q1 2026 (down from $5.355 million in Q1 2025).
- General and administrative expense: $1.369 million for Q1 2026 (down from $1.687 million in Q1 2025).
- Cash and cash equivalents: $1.272 million as of March 31, 2026 (down from $3.086 million at Dec. 31, 2025).
Business Highlights
- GEO-MVA: Advancing under an EMA-aligned expedited regulatory pathway with plans to initiate a Phase 3 immunobridging trial; Phase 3 execution activities underway including CRO selection and trial infrastructure activation.
- Manufacturing: Completion and release of cGMP clinical trial material and fill/finish product for clinical use; ongoing work on continuous cell-line manufacturing using the AGE1 platform for future scalable capacity.
- Phase 3 study design: Planned enrollment of approximately 500 participants to evaluate neutralizing antibody responses versus an approved MVA comparator using immunobridging endpoints.
- Immuno-oncology: Continued advancement of Gedeptin as a gene-directed enzyme prodrug therapy with focus on combination strategies with immune checkpoint inhibitors; exclusive license agreement with Emory University covering combinations with checkpoint inhibitors.
- Strategic focus: Prioritizing capital and operations toward GEO-MVA while maintaining Gedeptin development as a strategically important long-term optionality in combination immunotherapies.
Original SEC Filing: GeoVax Labs, Inc. [ GOVX ] - 8-K - May. 14, 2026